Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Inventory

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Inventory Disclosure

Merck & Co. Inc., balance sheet: inventory

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Finished goods
Raw materials and work in process
Supplies
Inventories, approximates current cost
Increase (decrease) to LIFO costs
Inventories
Less: Inventories recognized as other assets
Inventories, excludes inventories classified in Other assets

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


Overall inventory levels demonstrate a consistent upward trend from 2021 through 2025. However, a closer examination reveals differing patterns within inventory components and adjustments related to LIFO accounting. The reported inventory figures are also significantly impacted by the classification of certain inventories as other assets.

Finished Goods
Finished goods inventory exhibited steady growth, increasing from US$1,747 million in 2021 to US$2,275 million in 2025. This represents a cumulative increase of approximately 30.2% over the five-year period, indicating a potential increase in production or anticipated demand.
Raw Materials and Work in Process
Raw materials and work in process constitute the largest portion of total inventory. This component experienced substantial growth, rising from US$6,220 million in 2021 to US$10,645 million in 2025, a growth of approximately 71.1%. This significant increase could suggest rising input costs, expanded production capacity, or potential inefficiencies in the production cycle.
Supplies
Supplies inventory showed a moderate, consistent increase, moving from US$196 million in 2021 to US$331 million in 2025. This represents a growth of approximately 68.9% over the period, suggesting a proportional increase in operational needs.
Total Inventory (Approximated Current Cost)
Total inventory, approximated at current cost, increased from US$8,163 million in 2021 to US$13,251 million in 2025, representing a cumulative increase of approximately 62.4%. This growth aligns with the increases observed in the individual inventory components.
LIFO Adjustment
A consistent increase in the decrease to LIFO costs is observed. The adjustment moved from a decrease of US$16 million in 2021 to a decrease of US$912 million in 2025. This indicates that, under LIFO accounting, the cost of goods sold is being reduced, and ending inventory is being valued lower than it would be under FIFO. The magnitude of this adjustment is growing significantly over time.
Total Inventory (Reported)
Reported total inventory, after the LIFO adjustment, increased from US$8,147 million in 2021 to US$12,339 million in 2025, a growth of approximately 51.7%. This figure is lower than the total inventory approximated at current cost, due to the LIFO adjustment.
Inventories Classified as Other Assets
The amount of inventories recognized as other assets increased substantially, from US$2,194 million in 2021 to US$5,681 million in 2025. This represents a growth of approximately 159.1%. This significant increase reduces the amount of inventory reported on the balance sheet.
Inventory Excluding Other Assets
Inventory excluding inventories classified in other assets shows a more moderate increase, from US$5,953 million in 2021 to US$6,658 million in 2025. This represents a growth of approximately 11.9%. This figure provides a clearer picture of the inventory directly available for sale, and its growth is considerably less pronounced than the growth in total reported inventory.

The increasing classification of inventory as other assets warrants further investigation to understand the nature of these assets and the rationale for their classification. The substantial growth in raw materials and work in process, coupled with the increasing LIFO adjustment, should be monitored for potential impacts on cost of goods sold and profitability.


Adjustment to Inventory: Conversion from LIFO to FIFO

Adjusting LIFO Inventory to FIFO (Current) Cost

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Adjustment to Inventories
Inventories at LIFO (as reported)
Add: Inventory LIFO reserve
Inventories at FIFO (adjusted)
Adjustment to Current Assets
Current assets (as reported)
Add: Inventory LIFO reserve
Current assets (adjusted)
Adjustment to Total Assets
Total assets (as reported)
Add: Inventory LIFO reserve
Total assets (adjusted)
Adjustment to Total Merck & Co., Inc. Stockholders’ Equity
Total Merck & Co., Inc. stockholders’ equity (as reported)
Add: Inventory LIFO reserve
Total Merck & Co., Inc. stockholders’ equity (adjusted)
Adjustment to Net Income Attributable To Merck & Co., Inc.
Net income attributable to Merck & Co., Inc. (as reported)
Add: Increase (decrease) in inventory LIFO reserve
Net income attributable to Merck & Co., Inc. (adjusted)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The information presents a five-year trend of reported and adjusted financial figures for a company, reflecting an accounting change from the Last-In, First-Out (LIFO) to the First-In, First-Out (FIFO) inventory valuation method. The adjustments primarily impact inventory levels, current assets, total assets, and net income. A consistent pattern emerges where adjusted figures are generally higher than reported figures, indicating the FIFO method results in a higher valuation of inventory and, consequently, related balance sheet and income statement items.

Inventory Analysis
Reported inventories demonstrate a consistent upward trend from US$8,147 million in 2021 to US$12,339 million in 2025. The adjusted inventories, calculated under the FIFO method, exhibit a similar upward trajectory, starting at US$8,163 million in 2021 and reaching US$13,251 million in 2025. The difference between reported and adjusted inventories widens over time, suggesting a growing impact from the LIFO reserve. The largest absolute increase in reported inventory occurs between 2024 and 2025 (US$1,937 million), while the largest absolute increase in adjusted inventory also occurs during the same period (US$2,109 million).
Asset Impact
Both reported and adjusted current assets show an overall increasing trend throughout the period. Reported current assets rise from US$30,266 million in 2021 to US$43,516 million in 2025. The corresponding adjusted current assets increase from US$30,282 million to US$44,428 million. A similar pattern is observed for total assets, with reported totals increasing from US$105,694 million to US$136,866 million and adjusted totals increasing from US$105,710 million to US$137,778 million. The adjustments to total assets, driven by the inventory valuation change, remain relatively consistent as a percentage of reported total assets.
Equity and Net Income
Reported total stockholders’ equity fluctuates, decreasing from US$38,184 million in 2021 to US$37,581 million in 2023, then increasing to US$52,606 million in 2025. Adjusted stockholders’ equity follows a similar pattern, with minor differences. The impact of the inventory adjustment on equity is relatively small compared to the impact on asset values. Reported net income attributable to the company experiences significant volatility, with a substantial decrease in 2023 (US$365 million) followed by strong increases in 2024 and 2025. The adjusted net income mirrors this trend, though the magnitude of the adjustment is relatively consistent across the years, generally decreasing reported net income by a few hundred million dollars annually.

The transition from LIFO to FIFO appears to have a material impact on reported financial figures, particularly concerning asset valuation. The adjustments consistently increase reported values, reflecting the higher cost of goods sold typically associated with LIFO during periods of rising prices. The impact on net income is present but less substantial than the impact on balance sheet items. The consistent difference between reported and adjusted figures highlights the ongoing effect of this accounting method change.


Merck & Co. Inc., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: LIFO vs. FIFO (Summary)

Merck & Co. Inc., adjusted financial ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Current Ratio
Reported current ratio (LIFO)
Adjusted current ratio (FIFO)
Net Profit Margin
Reported net profit margin (LIFO)
Adjusted net profit margin (FIFO)
Total Asset Turnover
Reported total asset turnover (LIFO)
Adjusted total asset turnover (FIFO)
Financial Leverage
Reported financial leverage (LIFO)
Adjusted financial leverage (FIFO)
Return on Equity (ROE)
Reported ROE (LIFO)
Adjusted ROE (FIFO)
Return on Assets (ROA)
Reported ROA (LIFO)
Adjusted ROA (FIFO)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial metrics presented demonstrate generally consistent performance between reported and adjusted values across the examined period. Adjustments appear to primarily relate to inventory valuation methods, specifically the difference between Last-In, First-Out (LIFO) and First-In, First-Out (FIFO). The impact of these adjustments is relatively small, suggesting inventory is not a dominant factor in the overall financial picture.

Liquidity
The reported and adjusted current ratios exhibit similar trends. An increase is observed from 2021 to 2022, followed by a slight decrease in 2023, a recovery in 2024, and further improvement in 2025. The adjustments to the current ratio are minimal, indicating that changes in inventory valuation have a limited effect on short-term liquidity.
Profitability
Reported and adjusted net profit margins follow a similar pattern. A decline is seen from 2021 to 2022, a substantial drop in 2023, and then a strong recovery and increase through 2024 and 2025. The adjustments to net profit margin are small, suggesting inventory valuation does not significantly distort profitability measures. The significant dip in 2023 warrants further investigation beyond inventory adjustments.
Asset Utilization
The reported and adjusted total asset turnover ratios remain consistent. An increase is noted from 2021 to 2023, followed by a slight decrease in 2024, and a further decline in 2025. The adjustments have a negligible impact, indicating inventory valuation does not materially affect how efficiently assets are used to generate revenue.
Leverage
Financial leverage, both reported and adjusted, shows a decreasing trend from 2021 to 2022, followed by an increase in 2023, and a subsequent decrease in 2024 and 2025. The adjustments to financial leverage are minimal, suggesting inventory valuation has a limited influence on the company’s capital structure.
Return on Investment
Both reported and adjusted Return on Equity (ROE) and Return on Assets (ROA) mirror the trends observed in net profit margin. A decline from 2021 to 2022, a substantial decrease in 2023, and a strong recovery through 2024 and 2025 are evident. Adjustments to ROE and ROA are small, reinforcing the conclusion that inventory valuation has a limited impact on overall investment returns. The significant decline in 2023 for both ROE and ROA aligns with the observed drop in net profit margin and requires further scrutiny.

In summary, the adjustments related to inventory valuation have a consistently small impact on the reported financial ratios. The primary drivers of observed trends appear to be factors other than inventory costing methods. The substantial changes in profitability and returns in 2023, despite minimal adjustment effects, suggest a need for deeper analysis into the underlying causes of that year’s performance.


Merck & Co. Inc., Financial Ratios: Reported vs. Adjusted


Adjusted Current Ratio

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Adjusted: After Conversion from LIFO to FIFO
Selected Financial Data (US$ in millions)
Adjusted current assets
Current liabilities
Liquidity Ratio
Adjusted current ratio2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Adjusted current ratio = Adjusted current assets ÷ Current liabilities
= ÷ =


The adjusted current ratio exhibited a generally positive trend over the five-year period. While fluctuations were present, the metric demonstrated an overall increase, suggesting improving short-term liquidity. Reported current assets also showed an increasing trend, though with some volatility, mirroring the adjusted current asset values.

Adjusted Current Ratio Trend
The adjusted current ratio began at 1.27 in 2021 and increased to 1.49 in 2022, representing a notable improvement. It experienced a slight decrease to 1.27 in 2023 before rising again to 1.39 in 2024 and further to 1.57 in 2025. This indicates a strengthening ability to cover short-term liabilities with adjusted current assets.
Comparison of Reported and Adjusted Ratios
The reported current ratio and the adjusted current ratio remained consistently close in value across all observed periods. The adjustments made to current assets had a minimal impact on the overall ratio calculation, suggesting the adjustments were relatively small in magnitude.
Current Asset Movement
Adjusted current assets increased from US$30,282 million in 2021 to US$44,428 million in 2025. The largest year-over-year increase occurred between 2024 and 2025, with an addition of US$4,806 million. A dip was observed between 2022 and 2023, decreasing by US$3,285 million.

The observed increases in the adjusted current ratio, coupled with the growth in adjusted current assets, suggest a positive development in the company’s short-term financial position. The consistency between the reported and adjusted ratios implies that the adjustments applied are not fundamentally altering the assessment of liquidity.


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Sales
Profitability Ratio
Net profit margin1
Adjusted: After Conversion from LIFO to FIFO
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Merck & Co., Inc.
Sales
Profitability Ratio
Adjusted net profit margin2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Net profit margin = 100 × Net income attributable to Merck & Co., Inc. ÷ Sales
= 100 × ÷ =

2 Adjusted net profit margin = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Sales
= 100 × ÷ =


The period under review demonstrates fluctuating performance in net profit margins, both reported and adjusted. A significant divergence in reported net income is observed between 2022 and 2023, followed by substantial recovery in subsequent years. The adjusted net income mirrors this pattern, though with less extreme fluctuations.

Reported Net Profit Margin
The reported net profit margin experienced a decrease from 26.79% in 2021 to 24.49% in 2022. A dramatic decline occurred in 2023, falling to 0.61%. This was followed by a strong rebound to 26.68% in 2024 and further improvement to 28.08% in 2025. The volatility suggests sensitivity to underlying income fluctuations.
Adjusted Net Profit Margin
The adjusted net profit margin followed a similar trajectory to the reported margin. It decreased from 26.66% in 2021 to 24.96% in 2022. A substantial decrease was noted in 2023, reaching 1.05%. Subsequent years saw recovery, with the margin increasing to 27.11% in 2024 and 28.19% in 2025. The adjusted margin consistently remained slightly below the reported margin throughout the period.
Relationship between Reported and Adjusted Net Profit Margin
The difference between reported and adjusted net profit margins remained relatively small across all years, indicating that adjustments did not significantly alter the overall profitability picture. The largest difference was observed in 2023, where the adjusted margin was marginally higher than the reported margin, likely due to the impact of specific adjustments offsetting a larger decline in reported income. The convergence of both margins in 2024 and 2025 suggests a stabilization of underlying profitability drivers.
Overall Trend
Despite the significant dip in 2023, an overall upward trend in both reported and adjusted net profit margins is evident when considering the period from 2023 to 2025. This suggests improving operational efficiency or favorable market conditions in the later years of the review period. The substantial volatility in 2023 warrants further investigation to understand the underlying causes of the income decline.

Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Sales
Total assets
Activity Ratio
Total asset turnover1
Adjusted: After Conversion from LIFO to FIFO
Selected Financial Data (US$ in millions)
Sales
Adjusted total assets
Activity Ratio
Adjusted total asset turnover2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Total asset turnover = Sales ÷ Total assets
= ÷ =

2 Adjusted total asset turnover = Sales ÷ Adjusted total assets
= ÷ =


The adjusted total asset turnover ratio exhibited a fluctuating pattern over the five-year period. Initial increases were followed by a decline, suggesting shifts in the efficiency with which assets are utilized to generate sales.

Adjusted Total Asset Turnover Trend
The adjusted total asset turnover ratio began at 0.46 in 2021 and increased to 0.54 in both 2022 and 2023. This indicates improving efficiency in asset utilization during these years. However, the ratio decreased slightly to 0.54 in 2024 before falling to 0.47 in 2025. This recent decline suggests a potential decrease in the effectiveness of asset use in generating revenue.

Reported total assets and adjusted total assets followed a similar trajectory. Both metrics increased from 2021 to 2025, with a more substantial increase observed between 2023 and 2025. The consistency between reported and adjusted total assets suggests that adjustments made were not materially impacting the overall asset base.

Asset Base Growth
Adjusted total assets grew from US$105,710 million in 2021 to US$137,778 million in 2025, representing a cumulative increase of approximately 30.3%. The most significant year-over-year growth occurred between 2024 and 2025, with an increase of US$19,832 million. This expansion of the asset base did not translate into a corresponding increase in the asset turnover ratio in the most recent year.

The adjusted total asset turnover ratio and reported total asset turnover ratio remained identical across all observed years. This indicates that the adjustments made to total assets did not affect the calculated turnover ratio, suggesting the adjustments were not related to items directly impacting sales generation.

Ratio Consistency
The consistent values between the reported and adjusted total asset turnover ratios imply that the adjustments to total assets are not directly influencing the core operational efficiency reflected by the turnover ratio. This could be due to the nature of the adjustments, potentially relating to non-operating assets or accounting treatments that do not directly impact revenue generation.

The observed fluctuations in the adjusted total asset turnover ratio, coupled with the increasing asset base, warrant further investigation to determine the underlying drivers of these trends and assess their potential impact on future performance.


Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Total assets
Total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Financial leverage1
Adjusted: After Conversion from LIFO to FIFO
Selected Financial Data (US$ in millions)
Adjusted total assets
Adjusted total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Adjusted financial leverage2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= ÷ =


An examination of the financial information reveals trends in total assets, stockholders’ equity, and associated leverage ratios over a five-year period. Both reported and adjusted total assets experienced fluctuations, while stockholders’ equity generally increased. The reported and adjusted financial leverage ratios remained relatively stable, indicating a consistent capital structure throughout the period.

Total Assets
Reported total assets increased from US$105,694 million in 2021 to US$109,160 million in 2022, then decreased to US$106,675 million in 2023. A subsequent increase was observed in 2024, reaching US$117,106 million, followed by a further increase to US$136,866 million in 2025. Adjusted total assets mirrored this pattern, with values consistently slightly higher than reported assets.
Stockholders’ Equity
Reported total stockholders’ equity rose from US$38,184 million in 2021 to US$45,991 million in 2022. A decrease was then noted in 2023, falling to US$37,581 million, before increasing again to US$46,313 million in 2024 and US$52,606 million in 2025. Adjusted stockholders’ equity followed a similar trajectory, with minor differences in magnitude.
Financial Leverage
Reported financial leverage began at 2.77 in 2021, decreased to 2.37 in 2022, and then rose to 2.84 in 2023. It subsequently decreased to 2.53 in 2024 and remained relatively stable at 2.60 in 2025. Adjusted financial leverage exhibited a nearly identical pattern, consistently remaining close to the reported leverage ratio. The consistency between reported and adjusted leverage suggests that the adjustments made do not materially impact the overall assessment of financial risk related to capital structure.

The observed increases in both assets and equity, coupled with stable leverage ratios, suggest a period of growth and consistent financial management. The fluctuations in assets and equity between years warrant further investigation to understand the underlying drivers, but the overall trend indicates a strengthening financial position.


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Total Merck & Co., Inc. stockholders’ equity
Profitability Ratio
ROE1
Adjusted: After Conversion from LIFO to FIFO
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Merck & Co., Inc.
Adjusted total Merck & Co., Inc. stockholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROE = 100 × Net income attributable to Merck & Co., Inc. ÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =


The period under review demonstrates fluctuations in both reported and adjusted net income, alongside corresponding changes in total stockholders’ equity, impacting return on equity (ROE) calculations. A notable divergence in net income is observed between 2022 and 2023, followed by substantial increases in subsequent years. Stockholders’ equity generally increased, though a decrease occurred between 2022 and 2023, mirroring the net income trend.

Net Income Trends
Reported net income attributable to the company increased from US$13,049 million in 2021 to US$14,519 million in 2022. A significant decline occurred in 2023, falling to US$365 million, before rebounding strongly to US$17,117 million in 2024 and further increasing to US$18,254 million in 2025. Adjusted net income follows a similar pattern, with a decrease in 2023 and subsequent recovery, remaining consistently close to the reported figures.
Stockholders’ Equity Trends
Reported total stockholders’ equity rose from US$38,184 million in 2021 to US$45,991 million in 2022. A decrease was then recorded in 2023, with equity falling to US$37,581 million. This was followed by increases in 2024 and 2025, reaching US$46,313 million and US$52,606 million respectively. Adjusted total stockholders’ equity exhibits a similar trajectory, with minor differences in magnitude.
Reported ROE Analysis
Reported ROE peaked at 34.17% in 2021, decreased to 31.57% in 2022, and experienced a dramatic drop to 0.97% in 2023, coinciding with the decline in reported net income. A substantial recovery occurred in 2024, with ROE rising to 36.96%, and it remained relatively stable at 34.70% in 2025.
Adjusted ROE Analysis
Adjusted ROE mirrored the trends observed in reported ROE. It began at 33.99% in 2021, decreased to 31.97% in 2022, plummeted to 1.66% in 2023, and then recovered to 36.89% in 2024, concluding at 34.24% in 2025. The adjusted ROE values are consistently slightly lower than the reported ROE values across all periods.

The significant decline in both reported and adjusted ROE in 2023 warrants further investigation, as it corresponds with a substantial reduction in net income. The subsequent recovery in 2024 and 2025 suggests a return to more typical profitability levels. The close alignment between reported and adjusted ROE indicates that adjustments to net income and equity have a limited impact on the overall ROE calculation.


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Total assets
Profitability Ratio
ROA1
Adjusted: After Conversion from LIFO to FIFO
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Merck & Co., Inc.
Adjusted total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROA = 100 × Net income attributable to Merck & Co., Inc. ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Adjusted total assets
= 100 × ÷ =


The period between 2021 and 2025 demonstrates fluctuating, yet generally positive, performance in reported and adjusted return on assets. A significant anomaly occurred in 2023, followed by a recovery in subsequent years. The analysis below details these observations.

Overall ROA Trend
Both reported and adjusted ROA exhibited an increasing trend from 2021 to 2022. However, 2023 saw a substantial decline in both metrics. A strong recovery was then observed in 2024 and 2025, with both reported and adjusted ROA returning to levels comparable to, or slightly exceeding, those seen in 2022. The adjusted ROA consistently remained slightly below the reported ROA throughout the period.
ROA – 2021 to 2022
Reported ROA increased from 12.35% in 2021 to 13.30% in 2022, representing a roughly 7.7% increase. Adjusted ROA followed a similar pattern, rising from 12.28% to 13.52% over the same period, a roughly 10.1% increase. This suggests a period of improved profitability relative to asset base.
ROA – 2022 to 2023
A dramatic decrease in ROA occurred between 2022 and 2023. Reported ROA fell from 13.30% to 0.34%, while adjusted ROA decreased from 13.52% to 0.59%. This substantial decline indicates a significant reduction in profitability relative to the asset base during 2023. The cause of this decline would require further investigation.
ROA – 2023 to 2025
From 2023 to 2025, both reported and adjusted ROA experienced a considerable rebound. Reported ROA increased from 0.34% to 14.62% in 2024 and then slightly decreased to 13.34% in 2025. Adjusted ROA followed a similar trajectory, rising from 0.59% to 14.75% in 2024 and then decreasing to 13.30% in 2025. This recovery suggests a restoration of profitability and efficient asset utilization.
Asset Base
Reported total assets increased steadily from US$105,694 million in 2021 to US$136,866 million in 2025. Adjusted total assets mirrored this trend, increasing from US$105,710 million to US$137,778 million over the same period. The consistent growth in the asset base likely contributed to the overall ROA fluctuations, particularly in conjunction with the changes in net income.
Net Income Impact
Reported net income attributable to the company fluctuated significantly. It increased from US$13,049 million in 2021 to US$14,519 million in 2022, then plummeted to US$365 million in 2023, before rebounding to US$17,117 million in 2024 and US$18,254 million in 2025. Adjusted net income followed a similar pattern. These net income variations were a primary driver of the observed ROA changes.